Lawmakers send mixed messages on controlled substances
This article was originally published in Scrip
Lawmakers sent mixed messages during a 7 April hearing of the House Energy & Commerce Subcommittee on Health, in which the Drug Enforcement Administration (DEA) and the FDA were told to speed up their processes for scheduling controlled substances to get those products on the US marker quicker, while also upping their game on protecting the public from the epidemic of prescription drug abuse.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.